Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.32 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.31 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.31 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.31 |
| ▸ | CPB1 | P15086 | 1/20 | 0.30 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4976535 | 0.85 | FFAR1 (0.37) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL28114917 | 0.73 | FFAR1 (0.42) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL4308250 | 0.71 | NLN (0.53) | — | |
| SCHEMBL28967691 | 0.67 | LMNA (0.50) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL2230387 | 0.66 | KLK5 (0.49) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL4353465 | 0.65 | KLK5 (0.51) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL231952 | 0.65 | KLK5 (0.51) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL761986 | 0.64 | KLK5 (0.50) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL27220785 | 0.64 | KLK5 (0.53) | KLK5FFAR1SSTR1SSTR4NCOA3 | |
| SCHEMBL7950368 | 0.63 | CPB2 (0.35) | CPB1CPB2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 564 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6338945-B1 | CONCURRENT SCREENING OF OLIGOPEPTIDE LIBRARIES SYNTHESIZED ON SOLID PHASE SUPPORTS TO ISOLATE BIOACTIVE MOLECULES WHICH ELICIT CYTOLYTIC ACTIVITY | GENZYME CORPORATION | 2002-01-15 | — | — | US | claimed |
| US-20240189401-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-06-13 | — | — | US | disclosed |
| CN-113727990-B | Short synthetic peptides and their use for the treatment of retinal degenerative diseases and/or tissue damage | 曹友平 | 2024-05-28 | — | — | CN | disclosed |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | ALEXION PHARMA INC (US) | 2024-03-14 | — | — | US | disclosed |
| WO-2024035929-A2 | INSULIN SENSITIZERS FOR REVERSAL OF INSULIN RESISTANCE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-15 | — | — | WO | disclosed |
| US-11859015-B2 | Immunogenic WT-1 peptides and methods of use thereof | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-01-02 | — | — | US | disclosed |
| US-11839646-B2 | Antidotes for factor Xa inhibitors and methods of using the same | ALEXION PHARMACEUTICALS, INC. (US) | 2023-12-12 | — | — | US | disclosed |
| US-20230265122-A1 | IMMUNOGENIC WT-1 PEPTIDES AND METHODS OF USE THEREOF | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-08-24 | — | — | US | disclosed |
| CN-115920017-A | Methods and compositions for treating cancer | 纪念斯隆凯特林癌症中心 | 2023-04-07 | — | — | CN | disclosed |
| CN-110078813-B | Immunogenic WT-1 peptides and methods of use thereof | 纪念斯隆凯特林癌症中心 | 2023-03-28 | — | — | CN | disclosed |
| WO-1998038312-A1 | BACTERIAL ELASTIN BINDING PROTEIN, NUCLEIC ACID SEQUENCE ENCODING SAME AND DIAGNOSTIC AND THERAPEUTIC METHODS OF USE THEREOF | WASHINGTON UNIVERSITY (US) | 1998-09-03 | — | — | WO | disclosed |
| US-5650489-A | SOLID PHASE SYNTHESIS OF PEPTIDES, RANDOM SEQUENCES, COMBINATORIAL CHEMISTRY | THE ARIZONA BOARD OF REGENTS (US) | 1997-07-22 | — | — | US | disclosed |
| US-5510240-A | Method of screening a peptide library | THE ARIZONA BOARD OF REGENTS (US) | 1996-04-23 | — | — | US | disclosed |
| EP-0705279-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1996-04-10 | — | — | EP | disclosed |
| US-5470753-A | Peptide sequencing using mass spectrometry | SELECTIDE CORPORATION (US) | 1995-11-28 | — | — | US | disclosed |
| WO-1994028028-A1 | TOPOLOGICALLY SEGREGATED, ENCODED SOLID PHASE LIBRARIES | SELECTIDE CORPORATION (US) | 1994-12-08 | — | — | WO | disclosed |
| WO-1994006017-A1 | PEPTIDE SEQUENCING USING MASS SPECTROMETRY | SELECTIDE CORPORATION (US) | 1994-03-17 | — | — | WO | disclosed |
| EP-0542770-A4 | RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF USE THEREOF | — | 1993-09-15 | — | — | EP | disclosed |
| EP-0542770-A1 | RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF USE THEREOF | ARIZONA BOARD OF REGENTS a body corporate acting on behalf of Arizona State University (US) | 1993-05-26 | — | — | EP | disclosed |
| WO-1992000091-A1 | RANDOM BIO-OLIGOMER LIBRARY, A METHOD OF SYNTHESIS THEREOF, AND A METHOD OF USE THEREOF | BIOLIGAND, INC. (US) | 1992-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240189401-A1 | UNIT DOSE FORMULATION OF ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F8, F9 | KLK5 266/4885FFAR1 4161/4885SSTR1 3242/4885 |
| US-20240082367-A1 | ANTIDOTES FOR FACTOR XA INHIBITORS AND METHODS OF USING THE SAME | SERPINC1, F13B, F2 | KLK5 368/4885FFAR1 4654/4885SSTR1 4761/4885 |
| US-11839646-B2 | Antidotes for factor Xa inhibitors and methods of using the same | SERPINC1, F13B, HABP2 | KLK5 311/4885FFAR1 4683/4885SSTR1 4748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.